A common hereditary single-nucleotide polymorphism in the gene of FAS and colorectal cancer survival
Corresponding Author
Guenter Hofmann
Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria
Correspondence to: Guenter HOFMANN, M.D.,Division of Oncology, Department of Internal Medicine, Medical University of Graz,Auenbruggerplatz 15, 8036 Graz, Austria.Tel.: +43 316 385 3115Fax: +43 316 385 4167E-mail: [email protected]Search for more papers by this authorUwe Langsenlehner
Internal Outpatient Department, Steiermaerkische Gebietskrankenkasse, Graz, Austria
Search for more papers by this authorTanja Langsenlehner
Department of Therapeutic Radiology and Oncology, Medical University of Graz, Graz, Austria
Search for more papers by this authorBabak Yazdani-Biuki
Division of Rheumatology, Department of Internal Medicine, Medical University of Graz, Graz, Austria
Search for more papers by this authorHeimo Clar
Department of Orthopedic Surgery, Medical University of Graz, Graz, Austria
Search for more papers by this authorArmin Gerger
Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria
Search for more papers by this authorFlorentine Fuerst
Division of Rheumatology, Department of Internal Medicine, Medical University of Graz, Graz, Austria
Search for more papers by this authorHellmut Samonigg
Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria
Search for more papers by this authorPeter Krippl
Department of Internal Medicine, Regional Hospital of Fuerstenfeld, Fuerstenfeld, Austria
Search for more papers by this authorWilfried Renner
Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz, Austria
Search for more papers by this authorCorresponding Author
Guenter Hofmann
Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria
Correspondence to: Guenter HOFMANN, M.D.,Division of Oncology, Department of Internal Medicine, Medical University of Graz,Auenbruggerplatz 15, 8036 Graz, Austria.Tel.: +43 316 385 3115Fax: +43 316 385 4167E-mail: [email protected]Search for more papers by this authorUwe Langsenlehner
Internal Outpatient Department, Steiermaerkische Gebietskrankenkasse, Graz, Austria
Search for more papers by this authorTanja Langsenlehner
Department of Therapeutic Radiology and Oncology, Medical University of Graz, Graz, Austria
Search for more papers by this authorBabak Yazdani-Biuki
Division of Rheumatology, Department of Internal Medicine, Medical University of Graz, Graz, Austria
Search for more papers by this authorHeimo Clar
Department of Orthopedic Surgery, Medical University of Graz, Graz, Austria
Search for more papers by this authorArmin Gerger
Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria
Search for more papers by this authorFlorentine Fuerst
Division of Rheumatology, Department of Internal Medicine, Medical University of Graz, Graz, Austria
Search for more papers by this authorHellmut Samonigg
Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria
Search for more papers by this authorPeter Krippl
Department of Internal Medicine, Regional Hospital of Fuerstenfeld, Fuerstenfeld, Austria
Search for more papers by this authorWilfried Renner
Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz, Austria
Search for more papers by this authorAbstract
Apoptosis plays an important role in embryogenesis, autoimmunity and tumourigenesis. Cell surface death receptors such as TNFRSF6 (FAS) confer a major apoptotic effect. A single-nucleotide polymorphism in the FAS promoter gene, −670A/G, modulates apoptotic signalling and has been related to susceptibility and progression of a variety of cancers. The present study aimed to evaluate the role of this polymorphism for survival of patients with colorectal cancer. We performed a retrospective analysis including 433 patients with histologically confirmed colorectal cancer. A Cox regression model including FAS -670 genotypes, age at diagnosis, tumour grading, primary tumour size, number of lymph nodes examined, number of metastatic lymph nodes, tumour stage and application of fluorouracil-based adjuvant chemotherapy was used to estimate the effect of the FAS genotype on survival. FAS −670A/G genotype frequencies were 24.2% (AA), 46.3% (AG) and 29.5% (GG). Forty-nine patients were excluded from the Cox regression analysis because of missing values. Out of the remaining 384 patients, 69 (18%) died during a follow-up of maximum 10 years. Mean follow-up time was 58 ± 34 months (median 55 months). Carriers of the homozygous FAS -670GG genotype had a significantly lower survival rate compared with AA/AG genotype carriers (relative risk 1.76, 95% confidence interval 1.08–2.87; P= 0.023). The FAS −670A/G polymorphism may be associated with overall survival time of patients with colorectal cancer.
References
- 1 Parkin DM, Bray F, Ferlay J, et al . Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55: 74–108.
- 2 Jemal A, Siegel R, Ward E, et al . Cancer statistics, 2008. CA Cancer J Clin. 2008; 58: 71–96.
- 3 O’Brien DI, Nally K, Kelly RG, et al . Targeting the Fas/Fas ligand pathway in cancer. Expert Opin Ther Targets. 2005; 9: 1031–44.
- 4 Peter ME, Budd RC, Desbarats J, et al . The CD95 receptor: apoptosis revisited. Cell. 2007; 129: 447–50.
- 5 Wajant H. CD95L/FasL and TRAIL in tumour surveillance and cancer therapy. Cancer Treat Res. 2006; 130: 141–65.
- 6 Abrahams VM, Kamsteeg M, Mor G. The Fas/Fas ligand system and cancer: immune privilege and apoptosis. Mol Biotechnol. 2003; 25: 19–30.
- 7 Ferguson TA, Griffith TS. A vision of cell death: Fas ligand and immune privilege 10 years later. Immunol Rev. 2006; 213: 228–38.
- 8 Kim R, Emi M, Tanabe K, et al . The role of Fas ligand and transforming growth factor beta in tumor progression: molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy. Cancer. 2004; 100: 2281–91.
- 9 Huang QR, Morris D, Manolios N. Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. Mol Immunol. 1997; 34: 577–82.
- 10 Sibley K, Rollinson S, Allan JM, et al . Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia. Cancer Res. 2003; 63: 4327–30.
- 11 Crew KD, Gammon MD, Terry MB, et al . Genetic polymorphisms in the apoptosis-associated genes FAS and FASL and breast cancer risk. Carcinogenesis. 2007; 28: 2548–51.
- 12 Zhang B, Sun T, Xue L, et al . Functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer. Carcinogenesis. 2007; 28: 1067–73.
- 13 Zhang H, Sun XF, Synnerstad I, et al . Importance of FAS-1377, FAS-670, and FASL-844 polymorphisms in tumor onset, progression, and pigment phenotypes of Swedish patients with melanoma: a case-control analysis. Cancer J. 2007; 13: 233–7.
- 14 Kang S, Dong SM, Seo SS, et al . FAS-1377 G/A polymorphism and the risk of lymph node metastasis in cervical cancer. Cancer Genet Cytogenet. 2008; 180: 1–5.
- 15 Gaddipati H, Herlyn M. Association of polymorphisms of FAS-1377, FAS-670, and FASL-844 genes with risk factors for cutaneous malignant melanoma. Cancer J. 2007; 13: 226–8.
- 16 Jain M, Kumar S, Lal P, et al . Role of BCL2 (ala43thr), CCND1 (G870A) and FAS (A-670G) polymorphisms in modulating the risk of developing esophageal cancer. Cancer Detect Prev. 2007; 31: 225–32.
- 17 Krippl P, Langsenlehner U, Renner W, et al . Re: polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. J Natl Cancer Inst. 2004; 96: 1478–9.
- 18 Lai HC, Sytwu HK, Sun CA, et al . Single nucleotide polymorphism at Fas promoter is associated with cervical carcinogenesis. Int J Cancer. 2003; 103: 221–5.
- 19 Lerma E, Romero M, Gallardo A, et al . Prognostic significance of the Fas-receptor/Fas-ligand system in cervical squamous cell carcinoma. Virchows Arch. 2008; 452: 65–74.
- 20 Li C, Wu W, Liu J, et al . Functional polymorphisms in the promoter regions of the FAS and FAS ligand genes and risk of bladder cancer in south China: a case-control analysis. Pharmacogenet Genomics. 2006; 16: 245–51.
- 21 Lima L, Morais A, Lobo F, et al . Association between FAS polymorphism and prostate cancer development. Prostate Cancer Prostatic Dis. 2008; 11: 94–8.
- 22 Sun T, Miao X, Zhang X, et al . Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. J Natl Cancer Inst. 2004; 96: 1030–6.
- 23 Ueda M, Hung YC, Terai Y, et al . Fas gene promoter -670 polymorphism (A/G) is associated with cervical carcinogenesis. Gynecol Oncol. 2005; 98: 129–33.
- 24 Wang LE, Cheng L, Spitz MR, et al . Fas A670G polymorphism, apoptotic capacity in lymphocyte cultures, and risk of lung cancer. Lung Cancer. 2003; 42: 1–8.
- 25 Zhang Z, Wang LE, Sturgis EM, et al . Polymorphisms of FAS and FAS ligand genes involved in the death pathway and risk and progression of squamous cell carcinoma of the head and neck. Clin Cancer Res. 2006; 12: 5596–602.
- 26 Farre L, Bittencourt AL, Silva-Santos G, et al . Fas 670 promoter polymorphism is associated to susceptibility, clinical presentation, and survival in adult T cell leukemia. J Leukoc Biol. 2008; 83: 220–2.
- 27 Gerger A, Hofmann G, Langsenlehner U, et al . Integrin alpha-2 and beta-3 gene polymorphisms and colorectal cancer risk. Int J Colorectal Dis. 2009; 24: 159–63.
- 28 Hofmann G, Langsenlehner U, Renner W, et al . Common single nucleotide polymorphisms in the vascular endothelial growth factor gene and colorectal cancer risk. J Cancer Res Clin Oncol. 2008; 134: 591–5.
- 29 Wolpin BM, Mayer RJ. Systemic treatment of colorectal cancer. Gastroenterology. 2008; 134: 1296–310.
- 30 Compton CC, Greene FL. The staging of colorectal cancer: 2004 and beyond. CA Cancer J Clin. 2004; 54: 295–308.
- 31 Berger AC, Sigurdson ER, LeVoyer T, et al . Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes. J Clin Oncol. 2005; 23: 8706–12.
- 32 Johnson PM, Porter GA, Ricciardi R, et al . Increasing negative lymph node count is independently associated with improved long-term survival in stage IIIB and IIIC colon cancer. J Clin Oncol. 2006; 24: 3570–5.
- 33 Macdonald JS. Adjuvant therapy for colon cancer. CA Cancer J Clin. 1997; 47: 243–56.
- 34 Moertel CG, Fleming TR, Macdonald JS, et al . Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med. 1990; 322: 352–8.
- 35 Bennett MW, O’Connell J, Houston A, et al . Fas ligand upregulation is an early event in colonic carcinogenesis. J Clin Pathol. 2001; 54: 598–604.
- 36 O’Connell J, Bennett MW, Nally K, et al . Altered mechanisms of apoptosis in colon cancer: Fas resistance and counterattack in the tumor-immune conflict. Ann N Y Acad Sci. 2000; 910: 178–92.
- 37 Kanemitsu S, Ihara K, Saifddin A, et al . A functional polymorphism in fas (CD95/APO-1) gene promoter associated with systemic lupus erythematosus. J Rheumatol. 2002; 29: 1183–8.
- 38 Kim R, Emi M, Tanabe K, et al . Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res. 2006; 66: 5527–36.
- 39 Matsumoto N, Imamura R, Suda T. Caspase-8- and JNK-dependent AP-1 activation is required for Fas ligand-induced IL-8 production. FEBS J. 2007; 274: 2376–84.
- 40 Engelmark MT, Renkema KY, Gyllensten UB. No evidence of the involvement of the Fas -670 promoter polymorphism in cervical cancer in situ. Int J Cancer. 2004; 112: 1084–5.
- 41 Lai HC, Lin WY, Lin YW, et al . Genetic polymorphisms of FAS and FASL (CD95/CD95L) genes in cervical carcinogenesis: an analysis of haplotype and gene-gene interaction. Gynecol Oncol. 2005; 99: 113–8.
- 42 Sun T, Zhou Y, Li H, et al . FASL -844C polymorphism is associated with increased activation-induced T cell death and risk of cervical cancer. J Exp Med. 2005; 202: 967–74.